LifeSci Capital analyst Charles Zhu has maintained their bullish stance on IDYA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors that highlight IDEAYA Biosciences’ promising future prospects. The company is set to present new clinical data for their MAT2Ai IDE397 in combination with GILD’s Trodelvy, which could potentially enhance treatment options for patients with MTAP-mUC. Additionally, IDEAYA is progressing with their Darovasertib program, with significant data expected from both primary and metastatic UM patients.
IDEAYA’s robust pipeline is further supported by their strategic milestones, including a $10 million milestone from GSK and multiple IND filings planned by the end of 2025. The company’s financial health is also strong, with a cash runway extending into 2029, providing a solid foundation for continued research and development. These factors collectively underpin Charles Zhu’s positive outlook and Buy rating for IDEAYA Biosciences.